Capricor Therapeutics Stock Plummets After FDA Panel Rejects Duchenne Drug

Capricor Therapeutics (NASDAQ: CAPR) stock plunged 58.3% in pre-open trading Tuesday after a U.S. Food and Drug Administration advisory panel voted overwhelmingly against recommending its lead drug candidate, deramiocel. The committee's decision casts significant doubt on the drug's prospects for approval ahead of its August deadline.

FDA Panel Finds Evidence Lacking

On July 29, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against deramiocel. The panel concluded that the company's Phase 3 HOPE-3 trial did not provide substantial evidence of the drug's effectiveness in treating cardiomyopathy associated with Duchenne muscular dystrophy.

The vote followed a contentious meeting where Capricor and the FDA disagreed over the correct statistical analysis plan for the trial's data. Capricor CEO Linda Marbán stated to the committee that the FDA's briefing materials were based on an incomplete and unsigned draft plan, not the finalized version used for the study, according to Investing.com.

Analysts Slash Ratings and Price Targets

The negative panel outcome prompted a swift and severe reaction from Wall Street analysts, compounding pressure on the stock. Key downgrades include:

Ad

• Piper Sandler: Cut its rating from Overweight to Neutral and slashed its price target from $58 to $2.
• H.C. Wainwright: Moved its rating from Buy to Neutral and removed its price target, ascribing no clinical value to deramiocel.

These actions followed recent downgrades from B. Riley, Roth Capital, and Alliance Global Partners. Adding to negative sentiment, company insiders have sold approximately $3.1 million in stock over the past three months with no reported insider purchases.

What's Next for Capricor

The market is now pricing in a high probability of an outright rejection from the FDA. This would be the second time the agency has turned down the drug, following an initial rejection of its Biologics License Application (BLA) in July 2025. A second Complete Response Letter now appears to be the most likely outcome ahead of the August 22 PDUFA date, the FDA's deadline for a final decision.

With shares trading near $2.74—a fraction of their 52-week high of $40.37—investor focus may shift entirely to Capricor's earlier-stage exosome pipeline for any potential future value.